CN117363524B - Lactobacillus gasseri MY4 and application thereof in preparation of sleep-aiding and whitening medicines - Google Patents
Lactobacillus gasseri MY4 and application thereof in preparation of sleep-aiding and whitening medicines Download PDFInfo
- Publication number
- CN117363524B CN117363524B CN202311315806.5A CN202311315806A CN117363524B CN 117363524 B CN117363524 B CN 117363524B CN 202311315806 A CN202311315806 A CN 202311315806A CN 117363524 B CN117363524 B CN 117363524B
- Authority
- CN
- China
- Prior art keywords
- lactobacillus gasseri
- strain
- application
- aiding
- sleep
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000186606 Lactobacillus gasseri Species 0.000 title claims abstract description 88
- 239000003814 drug Substances 0.000 title abstract description 11
- 230000002087 whitening effect Effects 0.000 title abstract description 10
- 229940079593 drug Drugs 0.000 title abstract description 8
- 238000002360 preparation method Methods 0.000 title abstract description 7
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims abstract description 55
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims abstract description 46
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims abstract description 23
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims abstract description 23
- 239000006041 probiotic Substances 0.000 claims abstract description 22
- 235000018291 probiotics Nutrition 0.000 claims abstract description 22
- 230000000529 probiotic effect Effects 0.000 claims abstract description 20
- 108010024636 Glutathione Proteins 0.000 claims abstract description 16
- 108020004465 16S ribosomal RNA Proteins 0.000 claims description 6
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 claims description 5
- 101001076687 Lactobacillus gasseri Inulosucrase Proteins 0.000 claims description 5
- 239000003888 alpha glucosidase inhibitor Substances 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 230000000813 microbial effect Effects 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 229960003180 glutathione Drugs 0.000 abstract description 24
- 230000000694 effects Effects 0.000 abstract description 21
- 102100024295 Maltase-glucoamylase Human genes 0.000 abstract description 14
- 108010028144 alpha-Glucosidases Proteins 0.000 abstract description 14
- 230000006870 function Effects 0.000 abstract description 11
- 230000001603 reducing effect Effects 0.000 abstract description 10
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 7
- 210000004369 blood Anatomy 0.000 abstract description 7
- 239000008280 blood Substances 0.000 abstract description 7
- 239000008103 glucose Substances 0.000 abstract description 7
- 238000004519 manufacturing process Methods 0.000 abstract description 7
- 230000005764 inhibitory process Effects 0.000 abstract description 6
- 230000002550 fecal effect Effects 0.000 abstract description 5
- 230000028327 secretion Effects 0.000 abstract description 4
- 230000032683 aging Effects 0.000 abstract description 3
- 206010061218 Inflammation Diseases 0.000 abstract description 2
- 230000002075 anti-alcohol Effects 0.000 abstract description 2
- 230000004054 inflammatory process Effects 0.000 abstract description 2
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 230000007815 allergy Effects 0.000 abstract 1
- 230000003647 oxidation Effects 0.000 abstract 1
- 238000007254 oxidation reaction Methods 0.000 abstract 1
- 238000000855 fermentation Methods 0.000 description 15
- 230000004151 fermentation Effects 0.000 description 15
- 239000006228 supernatant Substances 0.000 description 9
- 230000005526 G1 to G0 transition Effects 0.000 description 8
- 210000001035 gastrointestinal tract Anatomy 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 7
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 125000003396 thiol group Chemical group [H]S* 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 230000003078 antioxidant effect Effects 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 230000000968 intestinal effect Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 4
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 4
- 230000003266 anti-allergic effect Effects 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 238000001784 detoxification Methods 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 229940116269 uric acid Drugs 0.000 description 4
- 241000282326 Felis catus Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 208000008589 Obesity Diseases 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 235000018417 cysteine Nutrition 0.000 description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 210000003617 erythrocyte membrane Anatomy 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 230000037356 lipid metabolism Effects 0.000 description 3
- 238000009630 liquid culture Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000002068 microbial inoculum Substances 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- 238000004321 preservation Methods 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 239000001888 Peptone Substances 0.000 description 2
- 108010080698 Peptones Proteins 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 235000015278 beef Nutrition 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 229940039696 lactobacillus Drugs 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 229940099596 manganese sulfate Drugs 0.000 description 2
- 235000007079 manganese sulphate Nutrition 0.000 description 2
- 239000011702 manganese sulphate Substances 0.000 description 2
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 235000019319 peptone Nutrition 0.000 description 2
- 239000004626 polylactic acid Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 238000006479 redox reaction Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- YWYZEGXAUVWDED-UHFFFAOYSA-N triammonium citrate Chemical compound [NH4+].[NH4+].[NH4+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O YWYZEGXAUVWDED-UHFFFAOYSA-N 0.000 description 2
- 239000001393 triammonium citrate Substances 0.000 description 2
- 235000011046 triammonium citrate Nutrition 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- TVZRAEYQIKYCPH-UHFFFAOYSA-N 3-(trimethylsilyl)propane-1-sulfonic acid Chemical compound C[Si](C)(C)CCCS(O)(=O)=O TVZRAEYQIKYCPH-UHFFFAOYSA-N 0.000 description 1
- 102100033639 Acetylcholinesterase Human genes 0.000 description 1
- 108010022752 Acetylcholinesterase Proteins 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 102000003914 Cholinesterases Human genes 0.000 description 1
- 108090000322 Cholinesterases Proteins 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102100039019 Nuclear receptor subfamily 0 group B member 1 Human genes 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 102100033220 Xanthine oxidase Human genes 0.000 description 1
- 108010093894 Xanthine oxidase Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229940022698 acetylcholinesterase Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003851 biochemical process Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000007177 brain activity Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 229940048961 cholinesterase Drugs 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 210000004953 colonic tissue Anatomy 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000004149 ethanol metabolism Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 206010023332 keratitis Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000003446 memory effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229920003168 pharmaceutical polymer Polymers 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 231100000216 vascular lesion Toxicity 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 238000012070 whole genome sequencing analysis Methods 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0215—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/40—Preparation of oxygen-containing organic compounds containing a carboxyl group including Peroxycarboxylic acids
- C12P7/42—Hydroxy-carboxylic acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
Abstract
The invention belongs to the technical field of probiotics and application thereof, and particularly relates to lactobacillus gasseri MY4 and application thereof in preparation of sleep-aiding and whitening medicines. In order to further develop and utilize the probiotic functions of lactobacillus gasseri, the invention separates and purifies a lactobacillus gasseri (MY 4 strain from a fecal sample of a healthy adult in Guangdong area of China, and the strain has various probiotic effects, including the production and secretion of gamma-aminobutyric acid, the inhibition of alpha-glucosidase activity and the production and secretion of glutathione. Therefore, the lactobacillus gasseri MY4 strain has the functions of anti-depression, anti-alcohol and sleep-aiding; reducing blood glucose; can resist oxidation and whiten skin, delay aging, resist inflammation and allergy, etc., for example, can be prepared into sleep-aiding and whitening medicines, and has important application value and economic value.
Description
Technical Field
The invention belongs to the technical field of probiotics and application thereof, and particularly relates to lactobacillus gasseri MY4 and application thereof in preparation of sleep-aiding and whitening medicines.
Background
Lactobacillus gasseri (Lactobacillus gasseri), also known as lactobacillus gasseri, is an anaerobic gram-positive bacterium belonging to the category of lactic acid bacteria, naturally occurring in the gastrointestinal tract, vagina or breast milk. Lactobacillus gasseri can survive and multiply in an acidic environment, which makes it viable in the environment of food and gastric acid. Lactobacillus gasseri is a member of the genus lactobacillus, which is able to convert carbohydrates into lactic acid by fermentation, thereby lowering the pH of the environment. In addition, lactobacillus gasseri has good acid and bile salt resistance, and can survive in intestines and stomach of human and animals.
Lactobacillus gasseri, defined by the us FDA as a generally recognized safety additive (GRAS) state microorganism, is one of the probiotic species that can be used in foods. Lactobacillus gasseri is widely present in the human and animal intestinal tract and is excreted with the feces. Lactobacillus gasseri is a part of the normal flora of the human body, which is an important component of the normal microbial system of the intestinal tract and is accompanied by a host for life, and has important significance for maintaining the microecological balance of the intestinal tract. In recent years, lactobacillus gasseri has become a hot spot of recent research as a probiotic lactobacillus having great potential, and is being continuously used to make probiotic preparations suitable for human and animals.
Studies have shown that different lactobacillus gasseri strains have different probiotic functions. Such as: (1) The lactobacillus gasseri TF08-1 strain can regulate lipid metabolism, reduce blood lipid, reduce related indexes of atherosclerosis related diseases and cardiovascular diseases, and remarkably reduce blood viscosity, thereby effectively preventing blood from being in a high viscosity and high coagulation state, improving hemorheology and vascular lesions; reducing liver burden and lipid metabolism disorder, thereby preventing fatty liver. (2) Lactobacillus gasseri LG08 can decompose most of uric acid synthesis precursor substances, reducing uric acid synthesis; can also decompose uric acid in intestinal tract, and further inhibit uric acid generation and relieve side effects such as inflammation by reducing serum endotoxin level and inhibiting xanthine oxidase activity. Thus, lactobacillus gasseri has the ability to break down purines and the ability to inhibit xanthine activity. (3) Lactobacillus gasseri G098 can alleviate DSS-induced colitis in mice by reducing mucosal damage to colonic tissue, modulating immune response, restoring intestinal flora diversity, and increasing intestinal flora stability. (4) Lactobacillus gasseri is beneficial to human body, and plays an important role in ecological balance and protection in intestinal tracts. It can regulate pH value of intestinal tract, inhibit growth of harmful bacteria and maintain normal flora structure of intestinal tract by producing lactic acid and other beneficial substances. Lactobacillus gasseri also helps to enhance immune system function, improve digestion and absorption, promote metabolism of nutrients, and prevent intestinal problems such as diarrhea and constipation.
Lactobacillus gasseri has genetic and functional diversity due to its source diversity. However, the current studies on the isolation and identification, the probiotic characteristics and the metabolic mechanism of the lactobacillus gasseri are still relatively few, which also affects the development and utilization of the lactobacillus gasseri to a certain extent. Therefore, it is necessary to dig different probiotic functions according to different sources of lactobacillus gasseri so as to make them function better, for example, determining the efficacy according to the functions of the strain or the probiotic metabolites, and defining the application prospect. In conclusion, the research and application of the probiotic lactobacillus gasseri have a very wide development space.
Disclosure of Invention
In order to overcome the defects in the prior art, the invention separates and purifies a strain of lactobacillus gasseri (Lactobacillus gasseri) MY4 from a fecal sample of a healthy adult in Guangdong area of China, and the strain has the functions of inhibiting the activity of alpha-glucosidase, generating and secreting glutathione and the like and has important potential application value.
In order to achieve the above purpose, the technical scheme adopted by the invention is as follows:
the first aspect of the present invention provides a lactobacillus gasseri (Lactobacillus gasseri) MY4 strain, wherein the lactobacillus gasseri MY4 strain is deposited with the China center for type culture collection (China, with a accession number: cctccc No. M20231159; the whole sequence of the 16S rDNA of the Lactobacillus gasseri MY4 strain is shown in SEQ ID No: 1.
In a second aspect, the invention provides the use of a strain of lactobacillus gasseri (Lactobacillus gasseri) MY4 as described in the first aspect for the production of gamma-aminobutyric acid.
The research shows that the probiotic lactobacillus gasseri MY4 strain can produce gamma-aminobutyric acid (GABA), which suggests that the lactobacillus gasseri MY4 strain can be used for producing GABA and can be used for improving the sleeping quality of organisms, resisting depression, resisting anxiety, reducing blood pressure, improving lipid metabolism and other fields by producing GABA.
In a third aspect, the invention provides the use of a strain of lactobacillus gasseri (Lactobacillus gasseri) MY4 as described in the first aspect for the production of reduced glutathione.
Through researches, the probiotic lactobacillus gasseri MY4 strain can produce reduced Glutathione (GSH), which suggests that the lactobacillus gasseri MY4 strain can be used for producing GSH, and can be used in the fields of antioxidation, whitening, aging delay, immunity enhancement, anti-tumor, antiallergic and the like through the characteristic of GSH production.
In a fourth aspect, the invention provides the use of a strain of lactobacillus gasseri (Lactobacillus gasseri) MY4 as described in the first aspect in the preparation of an α -glucosidase inhibitor.
Through researches, the probiotic lactobacillus gasseri MY4 strain can effectively inhibit the activity of alpha-glucosidase, and the alpha-glucosidase is related to type 2 diabetes, and the inhibition of the alpha-glucosidase is one of methods for controlling postprandial hyperglycemia, which suggests that the lactobacillus gasseri MY4 strain is expected to be used in the fields of reducing blood sugar, inhibiting obesity and the like.
In a fifth aspect the invention provides a probiotic functional bacterial agent comprising the lactobacillus gasseri (Lactobacillus gasseri) MY4 strain of the first aspect.
Preferably, the microbial inoculum is a fermented product of the lactobacillus gasseri (Lactobacillus gasseri) MY4 strain according to the first aspect.
Preferably, in the field of medical application, the microbial inoculum further comprises pharmaceutically acceptable auxiliary materials.
More preferably, the adjuvant comprises a carrier and an excipient. The excipient refers to diluents, binders, lubricants, disintegrants, cosolvents, stabilizers and the like which can be used in the pharmaceutical field and some medicinal matrixes. The carrier is a functional pharmaceutical adjuvant available in the pharmaceutical field and comprises a surfactant, a suspending agent, an emulsifying agent and a plurality of novel pharmaceutical polymer materials, such as cyclodextrin, chitosan, polylactic acid (PLA), polyglycolic acid-polylactic acid copolymer (PLGA), hyaluronic acid and the like.
Preferably, in the field of medical application, the dosage forms of the microbial inoculum comprise tablets, granules, capsules, dripping pills, sustained release agents, oral liquid preparations and injections.
More preferably, the above-mentioned dosage forms refer to clinically usual dosage forms. Pharmaceutical formulations may be administered orally or parenterally (e.g., intravenously, subcutaneously, intraperitoneally, or topically), and if some drugs are unstable under gastric conditions, they may be formulated as enteric coated tablets.
Compared with the prior art, the invention has the beneficial effects that:
the invention separates and purifies the excrement sample of a healthy adult in Guangdong area of China to obtain a strain of Lactobacillus gasseri (Lactobacillus gasseri) MY4, wherein the strain MY4 has various probiotics effects including the production and secretion of gamma-aminobutyric acid, the inhibition of alpha-glucosidase activity and the production and secretion of glutathione. Therefore, the lactobacillus gasseri MY4 strain has the functions of anti-depression, anti-alcohol and sleep-aiding; reducing blood glucose; has antioxidant, skin whitening, antiaging, antiinflammatory, and antiallergic effects. Therefore, the newly separated lactobacillus gasseri MY4 strain has various probiotics effects, can be used in the fields of sleep aiding, whitening and the like, for example, can be manufactured into sleep aiding and whitening medicines, and has important application value and economic value.
Drawings
FIG. 1 is a phylogenetic tree of Lactobacillus gasseri MY4 strain (strain is derived from Genome database of NCBI, wherein Lactobacillus gasseri MY is another strain declared by the inventors in the same time period, and the preservation number is CCTCC NO: M20231160);
FIG. 2 shows that Lactobacillus gasseri MY4 strain can produce and secrete gamma-aminobutyric acid;
FIG. 3 shows that the secretable material of the fermentation broth of Lactobacillus gasseri MY4 strain significantly inhibited the activity of α -glucosidase;
FIG. 4 shows that Lactobacillus gasseri strain MY4 can produce and secrete GSH.
Detailed Description
The following describes the invention in more detail. The description of these embodiments is provided to assist understanding of the present invention, but is not intended to limit the present invention. In addition, the technical features of the embodiments of the present invention described below may be combined with each other as long as they do not collide with each other.
The experimental methods in the following examples, unless otherwise specified, are conventional, and the experimental materials used in the following examples, unless otherwise specified, are commercially available.
The following examples relate to the following experimental materials:
(1) Lactobacillus gasseri (Lactobacillus gasseri) MY4 strain was isolated from a sample of intestinal faeces from a healthy adult (bmi=18.8) in guangzhou, china and placed in a glycerol tube for cryogenic storage at-80 ℃. In general, the strain is inoculated on the surface of a MRS solid culture medium flat plate and is reversely cultured for 24 hours in a constant temperature anaerobic incubator at 37 ℃ to obtain a bacterial colony, or is shake cultured for 24-48 hours in a MRS liquid culture medium in the constant temperature anaerobic incubator at 37 ℃ to obtain a fermentation broth.
(2) The kit comprises: gamma-aminobutyric acid (GABA) detection kit (Cloud-Clone corp., cat: CEA900 Ge), alpha-glucosidase inhibitor screening kit (abcam, cat: ab 284520), micro-reduced Glutathione (GSH) assay kit (Nanjing build, cat: a 006-2-1).
(3) MRS plate: 10g of beef extract, 10g of peptone, 5g of yeast extract, 2g of triammonium citrate, 5g of sodium acetate, 20g of glucose, 2g of dipotassium hydrogen phosphate, 1mL of Tween 80, 0.58g of magnesium sulfate, 0.25g of manganese sulfate, 15g of agar and ddH 2 Filling O to 1L, adjusting pH to 6.2-6.6, and autoclaving at 121deg.C for 20min to obtain MRS plate.
(4) MRS liquid medium: 10g of beef extract, 10g of peptone, 5g of yeast extract, 2g of triammonium citrate, 5g of sodium acetate, 20g of glucose, 2g of dipotassium hydrogen phosphate, 1mL of Tween 80, 0.58g of magnesium sulfate, 0.25g of manganese sulfate and ddH 2 Adding O to 1L, adjusting pH to 6.2-6.6, and autoclaving at 121deg.C for 20min to obtain MRS liquid culture medium.
EXAMPLE 1 isolation and identification of Lactobacillus gasseri (Lactobacillus gasseri) MY4 Strain
Lactobacillus gasseri Lactobacillus gasseriMY is isolated and purified from a intestinal fecal sample of a healthy adult (bmi=18.8) in guangzhou, china, and is specifically as follows:
the fecal sample was repeatedly washed 3 times with sterile water, placed in a mortar, 500uL of sterile water was added per 100mg of fecal sample, thoroughly ground to homogenate, and an appropriate amount of the grinding fluid was pipetted, spread on an MRS plate, and incubated at room temperature for 3 days. Colonies to be streaked and purified in the separation assay plates were then numbered with a marker and strain numbers were marked on the plates accordingly. After labelling, colonies were picked and inoculated onto MRS plates and the strains were purified by plate streaking. If the strain cannot be separated by the method, colonies need to be picked from the enrichment plate, and the colonies are coated on a culture medium after being subjected to gradient dilution by MRS liquid culture medium. Finally, reference is made to the "Burjie's Manual of identification of bacteria" (eighth edition) and the "manual of identification of classification of fungi", which identify the strains belonging to bacteria first, and then observe the growth of the colonies: the growth form, whether hypha exists or not, whether the color is uniform or not, and the surface and the edge of the colony individual are primarily separated to obtain a purified strain. The primary separation is carried out to obtain a purified strain, after 24 hours of culture, the colony of the strain is observed to be round, convex, smooth, neat in edge and opaque in milky white, and the strain number is MY4.
Next, the isolated MY4 strain was subjected to molecular characterization by 16S rDNA universal primer (27F: AGAGTTTGATCCTGGCTCAG,1492R: TACGGCTACCTTGTTACGACTT), and then subjected to whole genome sequencing by Beijing Baimaike Biotechnology Co. The resulting 16S rDNA sequence (SEQ ID No: 1) was subjected to BLAST alignment at NCBI' S Genome database. The results showed that the MY4 strain had >99% homology with the known 16S rDNA sequence of Lactobacillus gasseri (Lactobacillus gasseri) and was analyzed by evolution with the homologous strain (FIG. 1) to confirm that the strain MY4 was a different strain of Lactobacillus gasseri.
Finally, strain MY4 is preserved with the following information: preservation time: 2023, 7, 3; preservation unit name: china Center for Type Culture Collection (CCTCC); deposit number: cctccc No. M20231159; deposit unit address: chinese university of Wuhan; classification naming: lactobacillus gasseri.
Lactobacillus gasseri MY4 16S rDNA sequence(1437 bp，SEQ ID No：1)：
GTCGAGCGAGCTTGCCTAGATGAATTTGGTGCTTGCACCAAATGAAACTAGATACAAGCGAGCGGCGGACGGGTGAGTAACACGTGGGTAACCTGCCCAAGAGACTGGGATAACACCTGGAAACAGATGCTAATACCGGATAACAACACTAGACGCATGTCTAGAGTTTAAAAGATGGTTCTGCTATCACTCTTGGATGGACCTGCGGTGCATTAGCTAGTTGGTAAGGTAACGGCTTACCAAGGCAATGATGCATAGCCGAGTTGAGAGACTGATCGGCCACATTGGGACTGAGACACGGCCCAAACTCCTACGGGAGGCAGCAGTAGGGAATCTTCCACAATGGACGCAAGTCTGATGGAGCAACGCCGCGTGAGTGAAGAAGGGTTTCGGCTCGTAAAGCTCTGTTGGTAGTGAAGAAAGATAGAGGTAGTAACTGGCCTTTATTTGACGGTAATTACTTAGAAAGTCACGGCTAACTACGTGCCAGCAGCCGCGGTAATACGTAGGTGGCAAGCGTTGTCCGGATTTATTGGGCGTAAAGCGAGTGCAGGCGGTTCAATAAGTCTGATGTGAAAGCCTTCGGCTCAACCGGAGAATTGCATCAGAAACTGTTGAACTTGAGTGCAGAAGAGGAGAGTGGAACTCCATGTGTAGCGGTGGAATGCGTAGATATATGGAAGAACACCAGTGGCGAAGGCGGCTCTCTGGTCTGCAACTGACGCTGAGGCTCGAAAGCATGGGTAGCGAACAGGATTAGATACCCTGGTAGTCCATGCCGTAAACGATGAGTGCTAAGTGTTGGGAGGTTTCCGCCTCTCAGTGCTGCAGCTAACGCATTAAGCACTCCGCCTGGGGAGTACGACCGCAAGGTTGAAACTCAAAGGAATTGACGGGGGCCCGCACAAGCGGTGGAGCATGTGGTTTAATTCGAAGCAACGCGAAGAACCTTACCAGGTCTTGACATCCAGTGCAAACCTAAGAGATTAGGTGTTCCCTTCGGGGACGCTGAGACAGGTGGTGCATGGCTGTCGTCAGCTCGTGTCGTGAGATGTTGGGTTAAGTCCCGCAACGAGCGCAACCCTTGTCATTAGTTGCCATCATTAAGTTGGGCACTCTAATGAGACTGCCGGTGACAAACCGGAGGAAGGTGGGGATGACGTCAAGTCATCATGCCCCTTATGACCTGGGCTACACACGTGCTACAATGGACGGTACAACGAGAAGCGAACCTGCGAAGGTAAGCGGATCTCTGAAAGCCGTTCTCAGTTCGGACTGTAGGCTGCAACTCGCCTACACGAAGCTGGAATCGCTAGTAATCGCGGATCAGCACGCCGCGGTGAATACGTTCCCGGGCCTTGTACACACCGCCCGTCACACCATGAGAGTCTGTAACACCCAAAGCCGGTGGGATAACCTTTATAGGAGTCAGCCGTC。
Example 2 function of Lactobacillus gasseri (Lactobacillus gasseri) MY4 Strain and use thereof
(1) Lactobacillus gasseri MY4 strain can produce and secrete gamma-aminobutyric acid (GABA)
Lactobacillus gasseri MY4 cultured with MRS liquid medium to stationary phase was expanded into new MRS liquid medium at a dilution ratio of 1:30, bacterial suspension was collected at 24h of stationary phase, and after centrifugation at 10,000×g at 4 ℃ for 10min, the supernatant of the fermentation broth was collected, and then GABA concentration of the supernatant of the fermentation broth was measured by GABA specific ELISA kit (CEA 900 Ge). The results showed that the concentration of GABA in the fermentation supernatant of strain MY4 was significantly increased compared to the blank GABA control, and the accumulated amount was 233.90pg/mL, indicating that lactobacillus gasseri MY4 could produce and secrete γ -aminobutyric acid in the stationary phase (fig. 2).
Gamma-aminobutyric acid is an important central nervous system inhibitory neurotransmitter, and is widely present in animals, plants and microorganisms. It has been demonstrated that GABA, a small molecular weight non-protein amino acid, is food safe and can be used as a food additive. Research shows that intake of a certain amount of GABA has the physiological effects of improving sleeping quality of organisms, resisting depression, resisting anxiety, reducing blood pressure, improving lipid metabolism, enhancing memory and brain activity, accelerating brain metabolism, strengthening liver and kidney, promoting ethanol metabolism (dispelling alcohol effect), improving climacteric syndrome and the like.
Thus, the probiotic Lactobacillus gasseri strain MY4 can exert the above multiple uses by the effect of producing gamma-aminobutyric acid.
(2) The fermentation liquor of the Lactobacillus gasseri MY4 strain can effectively inhibit the activity of alpha-glucosidase
Lactobacillus gasseri MY4 cultured with MRS broth to stationary phase was expanded into new MRS broth at a dilution factor of 1:30, bacterial suspension was harvested at 24h of stationary phase, and fermentation broth supernatant was harvested after centrifugation at 10,000xg at 4 ℃ for 10min, and then the effect of fermentation broth supernatant on the enzymatic activity of alpha-glucosidase to hydrolyze glucose was determined by means of an alpha-glucosidase inhibitor screening kit (ab 284520). The results show that the fermentation supernatant of strain MY4 significantly inhibited the ability of alpha-glucosidase to hydrolyze glucose compared to the non-inhibitory effect of blank medium MRS, with an inhibition rate of about 7.90%, indicating that the fermentation broth of Lactobacillus gasseri MY4 can effectively inhibit the activity of alpha-glucosidase (FIG. 3).
a-glucosidase, an enzyme that plays a role in carbohydrate breakdown, is associated with type 2 diabetes, and inhibition of α -glucosidase is one of the methods of controlling postprandial hyperglycemia, thereby contributing to the treatment of diabetes. Thus, α -glucosidase inhibitors help to maintain blood glucose levels and can improve diabetic complications. Furthermore, inhibition of α -glucosidase activity may control obesity.
Thus, the probiotic lactobacillus gasseri MY4 strain has an inhibitory activity on a-glucosidase, which makes it a potential hypoglycemic and obesity inhibiting probiotic.
(3) Lactobacillus gasseri MY4 strain can produce and secrete reduced Glutathione (GSH)
The strain of Lactobacillus gasseri MY4 cultured in MRS liquid medium to stationary phase was expanded into new MRS liquid medium at a dilution ratio of 1:30, the bacterial suspension was collected at 24 hours of stationary phase, and after centrifugation at 10,000Xg and 4℃for 10 minutes, the supernatant of the fermentation broth was collected, and then the concentration of GSH in the supernatant of the fermentation broth was measured by reduced Glutathione (GSH) measuring kit (A006-2-1). The results showed that the concentration of GSH in the fermentation supernatant of strain MY4 was 249.04 μmol/L, the concentration of GSH after fermentation with MY4 was significantly increased (< 0.05) compared to the blank MRS control, indicating that lactobacillus gasseri MY4 can produce and secrete Glutathione (GSH) during stationary phase (fig. 4).
Glutathione (GSH) is a tripeptide consisting of glutamic acid, cysteine and glycine, and containing gamma-amide bond and mercapto group, and has antioxidant effect and integrated detoxification effect. The sulfhydryl group on cysteine is a glutathione reactive group (so glutathione is often abbreviated as GSH). Glutathione helps to maintain normal immune system function, has antioxidant and integrated detoxification effects, and plays an important role in various cell biochemical processes, such as free radical neutralization, detoxification, cysteine transport and storage, maintenance of cell redox, ascorbic acid and vitamin E regeneration, and the like. Mainly comprises the following aspects:
(1) detoxification: combined with poison or medicine to eliminate its toxic action;
(2) participate in the oxidation-reduction reaction: as an important reducing agent, participate in various oxidation-reduction reactions in the body;
(3) protection of thiol enzyme activity: maintaining the active group (-SH) of the sulfhydryl enzyme in a reduced state;
(4) maintenance of the stabilization of erythrocyte membrane structure: eliminating the damage of oxidant to erythrocyte membrane structure.
Thus, the various biological functions of GSH confer a variety of efficacy and utility, primarily represented by:
1) Antioxidant: scavenging free radicals in human bodies, protecting sulfhydryl groups in molecules such as a plurality of proteins, enzymes and the like from being oxidized by harmful substances, thereby ensuring the normal exertion of physiological functions of the proteins, the enzymes and the like; the content of glutathione in human erythrocytes is great, which has important significance for protecting the sulfhydryl group of protein on erythrocyte membrane in a reduced state and preventing hemolysis; it also has effects in preventing skin aging and pigmentation, reducing melanin formation, improving skin antioxidant capacity, and making skin luster.
2) Clinical medicine: the sulfhydryl chelates toxins such as heavy metals, fluoride, mustard gas and the like to prevent poisoning; can also be used as a medicament for treatment or adjuvant therapy in the aspects of hepatitis, hemolytic diseases, keratitis, cataract, retina diseases and the like; can also correct unbalance of acetylcholinesterase and cholinesterase, and has antiallergic effect.
3) Food additives: strengthening food nutrition, stabilizing vitamin C, and strengthening flavor.
In conclusion, the glutathione can be used for medicines and can be used as a base material of functional foods, and has wide application value in the fields of the functional foods such as antioxidation, whitening, aging delaying, immunity enhancing, anti-tumor, antiallergic and the like.
Taken together, the newly isolated lactobacillus gasseri (Lactobacillus gasseri) MY4 strain of the invention has various probiotic effects: (1) gamma-aminobutyric acid can be produced and secreted; (2) can inhibit alpha-glucosidase activity; (3) glutathione can be produced and secreted. Therefore, the novel isolated Lactobacillus gasseri MY4 strain has important application value and economic value.
The embodiments of the present invention have been described in detail above, but the present invention is not limited to the described embodiments. It will be apparent to those skilled in the art that various changes, modifications, substitutions and alterations can be made to these embodiments without departing from the principles and spirit of the invention, and yet fall within the scope of the invention.
Claims (6)
1. Lactobacillus gasseri strainLactobacillusgasseri) The strain MY4 is characterized in that the strain MY4 of the lactobacillus gasseri is preserved in China center for type culture Collection (China, accession number: cctccc No. M20231159; the whole sequence of the 16S rDNA of the Lactobacillus gasseri MY4 strain is shown in SEQ ID No: 1.
2. The Lactobacillus gasseri strain according to claim 1Lactobacillusgasseri) Application of MY4 strain in producing gamma-aminobutyric acid.
3. The Lactobacillus gasseri strain according to claim 1Lactobacillusgasseri) Application of MY4 strain in producing reduced glutathione.
4. The Lactobacillus gasseri strain according to claim 1Lactobacillusgasseri) Application of MY4 strain in preparing alpha-glucosidase inhibitor.
5. A microbial agent with a probiotic function is characterized by comprising the lactobacillus gasseri strain of claim 1Lactobacillusgasseri) MY4 strain.
6. The probiotic functional microbial agent according to claim 5, characterized in that in the field of medical applications, the microbial agent further comprises pharmaceutically acceptable excipients.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311315806.5A CN117363524B (en) | 2023-10-12 | 2023-10-12 | Lactobacillus gasseri MY4 and application thereof in preparation of sleep-aiding and whitening medicines |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311315806.5A CN117363524B (en) | 2023-10-12 | 2023-10-12 | Lactobacillus gasseri MY4 and application thereof in preparation of sleep-aiding and whitening medicines |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN117363524A CN117363524A (en) | 2024-01-09 |
| CN117363524B true CN117363524B (en) | 2024-03-22 |
Family
ID=89395786
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311315806.5A Active CN117363524B (en) | 2023-10-12 | 2023-10-12 | Lactobacillus gasseri MY4 and application thereof in preparation of sleep-aiding and whitening medicines |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117363524B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112458027A (en) * | 2020-12-16 | 2021-03-09 | 江南大学 | Lactobacillus gasseri and application thereof in relieving and treating hyperuricemia |
| CN114292766A (en) * | 2021-10-14 | 2022-04-08 | 卡士乳业(深圳)有限公司 | Lactobacillus gasseri with blood glucose reducing capability and application thereof |
| CN116555129A (en) * | 2023-07-11 | 2023-08-08 | 北京量化健康科技有限公司 | Lactobacillus gasseri BDUP, application and product thereof |
-
2023
- 2023-10-12 CN CN202311315806.5A patent/CN117363524B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112458027A (en) * | 2020-12-16 | 2021-03-09 | 江南大学 | Lactobacillus gasseri and application thereof in relieving and treating hyperuricemia |
| CN114292766A (en) * | 2021-10-14 | 2022-04-08 | 卡士乳业(深圳)有限公司 | Lactobacillus gasseri with blood glucose reducing capability and application thereof |
| CN116555129A (en) * | 2023-07-11 | 2023-08-08 | 北京量化健康科技有限公司 | Lactobacillus gasseri BDUP, application and product thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN117363524A (en) | 2024-01-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN116555076B (en) | Bifidobacterium longum subspecies longum MY1 and application thereof in preparation of food and medicine for relaxing bowels and protecting intestines | |
| CN115381860A (en) | Composition for protecting alcoholic liver injury and preparation method and application thereof | |
| CN117004503B (en) | Saliva combined lactobacillus MB1 and application thereof in preparation of food and medicine for assisting sleep and regulating intestines and stomach | |
| CN116555075B (en) | Lactobacillus plantarum JF1 and application thereof in preparation of anti-aging food and drug | |
| CN117264840A (en) | Lactobacillus brevis XY8 and application thereof in preparation of food and medicine for resisting aging and improving gout | |
| CN116555074B (en) | Lactobacillus brevis JT1 and application thereof in preparation of hypoglycemic drugs | |
| CN117363524B (en) | Lactobacillus gasseri MY4 and application thereof in preparation of sleep-aiding and whitening medicines | |
| CN115992059A (en) | Lactobacillus johnsonii for producing feruloyl esterase and application thereof in relieving ulcerative colitis | |
| CN117384788B (en) | Saliva combined lactobacillus SM4 and application thereof in preparation of whitening and cholesterol lowering foods and medicines | |
| CN117286045B (en) | Bifidobacterium longum subspecies longum KS2 and application thereof in preparation of anti-aging medicines | |
| CN116656526B (en) | Lactobacillus plantarum JF4 and application thereof in preparation of blood sugar and cholesterol reducing foods and medicines | |
| CN117946938A (en) | Lactobacillus plantarum SM3 and application thereof in preparation of blood sugar reducing and sleep-aiding foods and medicines | |
| CN116574634B (en) | Streptococcus salivarius thermophilus subspecies JF2 and application thereof in preparation of anti-inflammatory and lipid-relieving food and drug | |
| CN117946941A (en) | Lactobacillus plantarum MY6 and application thereof in preparation of anti-inflammatory, laxative and intestine-protecting food and medicine | |
| CN117946940A (en) | Lactobacillus plantarum SM1 and application thereof in preparing food and medicine for regulating intestines and stomach and losing weight | |
| CN117946939A (en) | Lactobacillus plantarum SM2 and application thereof in preparation of cholesterol-lowering and sleep-aiding foods and medicines | |
| CN115992076B (en) | Lactobacillus fermentum with blood sugar reducing function and application thereof | |
| CN116218733B (en) | Lactobacillus rhamnosus XY5 and application thereof in preparing antiallergic and digestion-promoting food and drug | |
| CN116286519B (en) | Lactobacillus paracasei KS3 and application thereof in preparation of anti-aging and digestion-aiding foods and medicines | |
| CN116376770B (en) | Application of lactobacillus rhamnosus RH0121 in preparation of hypoglycemic products | |
| CN117946936A (en) | Lactobacillus plantarum XY4 and application thereof in preparation of digestion-aiding and anti-inflammatory food and drug | |
| CN117866839A (en) | Enterococcus faecalis XY7 and application thereof in preparation of anti-inflammatory and gout-improving foods and medicines | |
| CN117946942A (en) | Lactobacillus plantarum MY3 and application thereof in preparing food and medicine for regulating intestines and stomach and improving constipation | |
| CN117946937A (en) | Lactobacillus plantarum XY1 and application thereof in preparation of foods and medicines for reducing blood sugar and improving gout | |
| CN117384789A (en) | Pediococcus pentosaceus KS5 and application thereof in preparation of antioxidant and anti-aging food and drug |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |